Paratek Pharmaceuticals Price Prediction

PRTKDelisted Stock  USD 2.18  0.00  0.00%   
The value of RSI of Paratek Pharmaceuticals' the stock price is about 60 indicating that the stock is rather overbought by investors as of now. The main point of the Relative Strength Index (RSI) is to track how fast people are buying or selling Paratek, making its price go up or down.

Oversold Vs Overbought

60

 
Oversold
 
Overbought
The successful prediction of Paratek Pharmaceuticals' future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with Paratek Pharmaceuticals, which may create opportunities for some arbitrage if properly timed.
Using Paratek Pharmaceuticals hype-based prediction, you can estimate the value of Paratek Pharmaceuticals from the perspective of Paratek Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Paratek Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Paratek because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Paratek Pharmaceuticals after-hype prediction price

    
  USD 2.18  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as delisted stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Paratek Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
1.731.732.40
Details
Naive
Forecast
LowNextHigh
2.322.322.32
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
2.182.192.20
Details

Paratek Pharmaceuticals After-Hype Price Prediction Density Analysis

As far as predicting the price of Paratek Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Paratek Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Paratek Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Paratek Pharmaceuticals Estimiated After-Hype Price Volatility

In the context of predicting Paratek Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Paratek Pharmaceuticals' historical news coverage. Paratek Pharmaceuticals' after-hype downside and upside margins for the prediction period are 2.18 and 2.18, respectively. We have considered Paratek Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
2.18
2.18
After-hype Price
2.18
Upside
Paratek Pharmaceuticals is very steady at this time. Analysis and calculation of next after-hype price of Paratek Pharmaceuticals is based on 3 months time horizon.

Paratek Pharmaceuticals Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Paratek Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Paratek Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Delisted Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Paratek Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
 0.00  
0.00
 0.00  
 0.00  
2 Events / Month
8 Events / Month
In a few days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
2.18
2.18
0.00 
0.00  
Notes

Paratek Pharmaceuticals Hype Timeline

Paratek Pharmaceuticals is at this time traded for 2.18. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Paratek is anticipated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is anticipated to be very small, whereas the daily expected return is at this time at 0.0%. %. The volatility of related hype on Paratek Pharmaceuticals is about 0.0%, with the expected price after the next announcement by competition of 2.18. About 55.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.11. Paratek Pharmaceuticals last dividend was issued on the 31st of October 2014. The entity had 1:12 split on the 31st of October 2014. Given the investment horizon of 90 days the next anticipated press release will be in a few days.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Paratek Pharmaceuticals Related Hype Analysis

Having access to credible news sources related to Paratek Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Paratek Pharmaceuticals' future price movements. Getting to know how Paratek Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Paratek Pharmaceuticals may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
CRVSCorvus Pharmaceuticals(0.88)7 per month 2.98  0.23  9.38 (4.88) 23.11 
IMMPImmutep Ltd ADR 0.02 3 per month 0.00 (0.12) 5.02 (5.56) 18.55 
ICVXIcosavax(0.11)1 per month 4.56  0.13  10.22 (6.79) 38.57 
LYRALyra Therapeutics(0.01)4 per month 0.00 (0.11) 8.00 (10.00) 41.07 
EQEquillium(0.02)8 per month 0.00 (0.05) 13.33 (9.35) 64.12 
HOOKHookipa Pharma(0.19)7 per month 0.00 (0.35) 6.51 (7.24) 22.98 
LIANLianBio ADR 0.00 0 per month 3.34  0.01  6.76 (5.00) 20.98 
JSPRJasper Therapeutics 1.41 8 per month 4.82  0.04  9.08 (8.03) 24.85 
AFMDAffimed NV 0.42 8 per month 0.00 (0.15) 7.25 (6.82) 21.26 
LPTXLeap Therapeutics 0.05 4 per month 4.32 (0.02) 11.08 (7.03) 25.59 
ADAPAdaptimmune Therapeutics Plc(0.01)8 per month 0.00 (0.23) 5.56 (6.00) 32.97 
APTOAptose Biosciences(0.05)7 per month 0.00 (0.21) 5.41 (7.69) 33.33 

Paratek Pharmaceuticals Additional Predictive Modules

Most predictive techniques to examine Paratek price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Paratek using various technical indicators. When you analyze Paratek charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Paratek Pharmaceuticals Predictive Indicators

The successful prediction of Paratek Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Paratek Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Paratek Pharmaceuticals based on analysis of Paratek Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Paratek Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Paratek Pharmaceuticals's related companies.

Story Coverage note for Paratek Pharmaceuticals

The number of cover stories for Paratek Pharmaceuticals depends on current market conditions and Paratek Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Paratek Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Paratek Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Paratek Pharmaceuticals Short Properties

Paratek Pharmaceuticals' future price predictability will typically decrease when Paratek Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Paratek Pharmaceuticals often depends not only on the future outlook of the potential Paratek Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Paratek Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding54.4 M
Cash And Short Term Investments34.2 M
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Other Consideration for investing in Paratek Stock

If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation